Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Carolina Punziano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Italy. Hauptthemen laut MEDLINE: Dimethyl Fumarate, Cisplatin, Uterine Cervical Neoplasms, Tumor Suppressor Protein p53. Die Arbeit nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Fondazione AIRC per la ricerca sul cancro ETS.
Abstract (Originalsprache)
Cervical cancer is one of the leading causes of tumor‐related deaths among women. Chemotherapy in cervical cancer is mainly based on cisplatin, but this drug has limited efficacy; therefore, alternative treatment options are needed. Ferroptosis represents a novel form of cell death. In cervical epithelium, ferroptosis occurs in the early neoplastic stages of papillomavirus infection but shifts to evasion in carcinoma. Combination therapy has the potential to enhance cancer cell death and overcome resistance development. Herein we demonstrate that dimethyl fumarate (DMF), a Food and Drug Administration (FDA)‐approved anti‐inflammatory drug, induces ferroptosis in cervical cancer cells in a dose‐dependent manner and inhibits growth in spheroid models. Cotreatment with DMF and cisplatin significantly decreases cell viability compared to either drug alone. Under DMF/cisplatin combination, cervical cancer cells underwent to glutathione depletion and p53 (re)activation, leading to cell death by both ferroptosis and apoptosis. We found a p53‐mediated downregulation of the Solute Carrier Family 7 Member 11 (SLC7A11)/Cystine/Glutamate Transporter (xCT) expression and glutathione levels. Our results suggest that combined administration of DMF and cisplatin, by targeting the dependency of cervical cancer cells on glutathione and (re)activating p53, represents a promising anticancer therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Italy.
- Department of Biology, University of Rome Tor Vergata, Italy.
- Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
ORCID-Profile: Raffaella Faraonio
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Punziano, C., Minopoli, G., Romano, S., Marrone, L., Aquilano, K., Tornesello, M. L., & Faraonio, R. (2026). Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation. Molecular Oncology. https://doi.org/10.1002/1878-0261.70216
Vancouver
Punziano C, Minopoli G, Romano S, Marrone L, Aquilano K, Tornesello ML, et al. Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation. Molecular Oncology. 2026. doi:10.1002/1878-0261.70216
BibTeX
@article{Punziano2026,
author = {Punziano, Carolina and Minopoli, Giuseppina and Romano, Simona and Marrone, Laura and Aquilano, Katia and Tornesello, Maria Lina and Faraonio, Raffaella},
title = {Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70216}
}
EUVIMED